GH Research PLC

The current price of GHRS is $18.44 — it has decreased by 7.48% since the previous close. Data as of Nov 5, 2026.

GHRS is down 13.26% over the past week, down 16.82% over the past month and up 35.69% over the past year. The price is below its 200-day moving average of $21.60.

Analysts' average 12-month price target for GHRS is $48.83, which implies 164.80% upside from the current price. Individual estimates range from $39.00 to $65.00.

Of the 10 analysts covering GH Research PLC, 3 rate it a strong buy and 7 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

GH Research PLC has a market capitalization of $1.27B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, GH Research PLC posted a loss of $0.23 per share against an estimate of -$0.286, beating expectations by 19.58%. Upcoming reports are listed in the earnings calendar.

GH Research PLC has not paid any dividends over the past year.

Companies most comparable to GH Research PLC include Definium Therapeutics, Inc., Biohaven Ltd., LB Pharmaceuticals Inc Common Stock, Rapport Therapeutics, Inc. Common Stock and Seaport Therapeutics, Inc. Common Stock.

In the latest trading session GHRS moved between $18.32 and $19.81, a range of 8.08% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of GH Research PLC shows a strong sell rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for GH Research PLC is buy. Technical ratings are indicators, not investment advice.

Over the past 52 weeks GHRS has traded between $12.04 and $31.44. The current price is 41.35% below its 52-week high.